Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice

碩士 === 國防醫學院 === 微生物及免疫學研究所 === 91 === Insulin-dependent diabetes mellitus (IDDM), also named type I, or juvenile-onset diabetes, is a kind of autoimmune disease. The non-obese diabetic (NOD) mouse, an inbred strain that spontaneously develops autoimmune diabetes resembling human IDDM is...

Full description

Bibliographic Details
Main Authors: Tan-Mei Liu, 劉譚美
Other Authors: Huey-Kang Sytwu
Format: Others
Language:zh-TW
Published: 2003
Online Access:http://ndltd.ncl.edu.tw/handle/40387591323602363713
id ndltd-TW-091NDMC0380001
record_format oai_dc
spelling ndltd-TW-091NDMC03800012016-06-22T04:20:05Z http://ndltd.ncl.edu.tw/handle/40387591323602363713 Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice 第三號誘餌受體對非肥胖型糖尿病小鼠骨髓樹突狀細胞之免疫調控效應 Tan-Mei Liu 劉譚美 碩士 國防醫學院 微生物及免疫學研究所 91 Insulin-dependent diabetes mellitus (IDDM), also named type I, or juvenile-onset diabetes, is a kind of autoimmune disease. The non-obese diabetic (NOD) mouse, an inbred strain that spontaneously develops autoimmune diabetes resembling human IDDM is a widely used animal model for dissecting immunopathological mechanisms in IDDM and developing preventive and/or therapeutic strategies. Decoy receptor 3 (DcR3) belongs to the tumor necrosis factor (TNF) receptor superfamily and is first found to be overexpressed by malignant tumors arising from pulmonary and gastrointestinal tract. DcR3 can bind with FasL and inhibit T-lymphocytes induced apoptosis that may be one of the possible mechanisms for tumor cells to escape the immunosurveillance. It has recently been reported that DcR3-treated dendritic cells (DCs) that differentiated from human peripheral monocytes, expressed higher level of CD86 and biased T cell differentiation to the T helper 2 (Th2) phenotype. Therefore, in this study, we tested whether DcR3 can modulate the differentiation and maturation of bone marrow-derived DCs (BM-DCs) from NOD mice, and induced T cell differentiation to the Th2 phenotype. Our study revealed that CD86 was up-regulated, and CD11c, CD80, CD40, and MHC I-Ag7 were down-regulated, and CD54 were not affected on DcR3.Fc-treated DCs. The proliferation of CD4+ T cells co-cultured with DcR3.Fc-treated DCs was significantly decreased, when compared to that of T cells stimulated by regular DCs. Furthermore, we found DcR3.Fc-treated DCs had higher ERK MAP kinase activity and MAP kinase-mediated signal transduction is involved in DC maturation and function. The use of MAP kinase inhibitors also help us to understand that the distribution of surface markers of DCs related to cytokine secretion and the expression of MAP kinase. Huey-Kang Sytwu 司徒惠康 2003 學位論文 ; thesis 79 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國防醫學院 === 微生物及免疫學研究所 === 91 === Insulin-dependent diabetes mellitus (IDDM), also named type I, or juvenile-onset diabetes, is a kind of autoimmune disease. The non-obese diabetic (NOD) mouse, an inbred strain that spontaneously develops autoimmune diabetes resembling human IDDM is a widely used animal model for dissecting immunopathological mechanisms in IDDM and developing preventive and/or therapeutic strategies. Decoy receptor 3 (DcR3) belongs to the tumor necrosis factor (TNF) receptor superfamily and is first found to be overexpressed by malignant tumors arising from pulmonary and gastrointestinal tract. DcR3 can bind with FasL and inhibit T-lymphocytes induced apoptosis that may be one of the possible mechanisms for tumor cells to escape the immunosurveillance. It has recently been reported that DcR3-treated dendritic cells (DCs) that differentiated from human peripheral monocytes, expressed higher level of CD86 and biased T cell differentiation to the T helper 2 (Th2) phenotype. Therefore, in this study, we tested whether DcR3 can modulate the differentiation and maturation of bone marrow-derived DCs (BM-DCs) from NOD mice, and induced T cell differentiation to the Th2 phenotype. Our study revealed that CD86 was up-regulated, and CD11c, CD80, CD40, and MHC I-Ag7 were down-regulated, and CD54 were not affected on DcR3.Fc-treated DCs. The proliferation of CD4+ T cells co-cultured with DcR3.Fc-treated DCs was significantly decreased, when compared to that of T cells stimulated by regular DCs. Furthermore, we found DcR3.Fc-treated DCs had higher ERK MAP kinase activity and MAP kinase-mediated signal transduction is involved in DC maturation and function. The use of MAP kinase inhibitors also help us to understand that the distribution of surface markers of DCs related to cytokine secretion and the expression of MAP kinase.
author2 Huey-Kang Sytwu
author_facet Huey-Kang Sytwu
Tan-Mei Liu
劉譚美
author Tan-Mei Liu
劉譚美
spellingShingle Tan-Mei Liu
劉譚美
Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
author_sort Tan-Mei Liu
title Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
title_short Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
title_full Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
title_fullStr Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
title_full_unstemmed Immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
title_sort immunomodulatory effect of decoy receptor 3 on bone marrow-derived dendritic cells from non-obese diabetic mice
publishDate 2003
url http://ndltd.ncl.edu.tw/handle/40387591323602363713
work_keys_str_mv AT tanmeiliu immunomodulatoryeffectofdecoyreceptor3onbonemarrowderiveddendriticcellsfromnonobesediabeticmice
AT liútánměi immunomodulatoryeffectofdecoyreceptor3onbonemarrowderiveddendriticcellsfromnonobesediabeticmice
AT tanmeiliu dìsānhàoyòuěrshòutǐduìfēiféipàngxíngtángniàobìngxiǎoshǔgǔsuǐshùtūzhuàngxìbāozhīmiǎnyìdiàokòngxiàoyīng
AT liútánměi dìsānhàoyòuěrshòutǐduìfēiféipàngxíngtángniàobìngxiǎoshǔgǔsuǐshùtūzhuàngxìbāozhīmiǎnyìdiàokòngxiàoyīng
_version_ 1718317001757163520